How to Get Peptides Prescribed in 2026
The step-by-step process from deciding you want peptide therapy to receiving your first shipment from a licensed compounding pharmacy. What it takes, what it costs, and what to watch out for.
You’ve read the research. You’ve followed the regulatory news. You know that BPC-157 and five other peptides received favorable PCAC recommendations, and that the 503A compounding pathway is the route to legal access. Now you want to know the actual process: how do you go from “interested” to “prescription in hand”?
Here is every step, in order, with realistic expectations about what each one involves and costs. No part of this process requires an in-person visit. Everything can be done through telehealth.
Choose Your Path: Telehealth vs In-Person
Complete the entire process from home. Video consultation with a licensed provider, bloodwork at a local lab or via a mail-in kit, prescription shipped from a compounding pharmacy.
+ Convenient, nationwide access, no waiting room
+ Providers who specialize in peptide therapy
~ Higher cost than some in-person clinics
~ Less hands-on guidance for injection technique
Visit a regenerative medicine, anti-aging, or functional medicine clinic. On-site bloodwork, face-to-face consultation, hands-on injection training.
+ In-person guidance, especially for first-time injectors
+ May offer in-office treatments
~ Limited by geography — peptide-knowledgeable clinics aren’t everywhere
~ Often more expensive for the consultation itself
For most people in 2026, telehealth is the more practical path. The provider landscape for peptide therapy has matured significantly, with multiple platforms offering licensed-physician consultations, integrated bloodwork ordering, and direct-ship from partner compounding pharmacies. The process below works for either path, but the telehealth flow is what most patients follow.
The Process, Step by Step
Every legitimate provider starts here. You’ll fill out a detailed health questionnaire covering your medical history, current medications, allergies, past surgeries, and the specific health goal you’re trying to address with peptide therapy. This is not a formality — it’s the clinical foundation for everything that follows.
Be specific about your goal. “I want BPC-157” is a product request, not a clinical goal. “I have a chronic tendon issue in my left shoulder that hasn’t responded to PT” is a clinical goal. Providers make prescribing decisions based on clinical indications, not product preferences.
Before prescribing, your provider needs to see where your body is starting from. The specific panels depend on which peptides are being considered, but most providers require at minimum a comprehensive metabolic panel (CMP) and complete blood count (CBC).
Depending on your situation and the peptides under consideration, you may also need IGF-1 levels (particularly for growth-hormone-related peptides like CJC-1295), inflammatory markers (CRP, ESR — especially for BPC-157 and recovery applications), a thyroid panel (TSH, free T3/T4), fasting insulin, and a lipid panel.
Some telehealth platforms order labs through partner networks (Quest, Labcorp, or direct-to-consumer services). Others accept recent results from your primary care physician, typically within the last 60–90 days.
This is the clinical decision point. A licensed physician, nurse practitioner, or physician assistant reviews your intake, bloodwork, and health goals. The consultation typically runs 15–45 minutes via video call.
A good provider will discuss which peptides are appropriate for your specific situation, explain the evidence base (including its limitations — most peptide research is preclinical), outline the expected protocol including dosing and duration, review potential side effects and contraindications, and set expectations for follow-up and monitoring.
This is also where you should ask questions. What is the clinical rationale for this peptide over alternatives? How will we monitor progress? What labs will we recheck and when? What are the signs I should contact you?
If the provider determines peptide therapy is clinically appropriate, they write a prescription and send it to a licensed 503A compounding pharmacy. Most telehealth platforms have established pharmacy partnerships, so this step happens behind the scenes.
The pharmacy sources pharmaceutical-grade raw materials, compounds your specific prescription (dose, form factor, quantity), performs appropriate quality testing, and prepares it for shipment. Peptide prescriptions are typically for a 30-day supply.
If you are working with an in-person provider who does not have a pharmacy relationship, ask for a recommendation. Not every compounding pharmacy handles peptides — you need one that does sterile compounding (USP 797 compliant) and works with peptide-grade substances.
Compounded peptides arrive cold-shipped in insulated packaging. Injectable peptides typically arrive as lyophilized (freeze-dried) powder in a vial, along with bacteriostatic water (BAC water) for reconstitution. Oral peptides arrive as capsules. Nasal sprays arrive ready to use.
Your shipment should include the medication as prescribed, clear labeling with your name, the substance, concentration, and beyond-use date, reconstitution instructions if applicable, and storage instructions (most reconstituted peptides require refrigeration at 2–8°C).
If you are doing injectable peptides for the first time and are unsure about reconstitution or injection technique, most telehealth providers offer instructional resources or follow-up calls. This is a reasonable thing to ask for — proper technique matters for safety and efficacy.
Peptide therapy is not a one-and-done prescription. Legitimate providers schedule follow-up labs and consultations to monitor your response. The cadence depends on the peptide and the clinical context, but a typical rhythm is a check-in at 4–6 weeks, follow-up bloodwork at 8–12 weeks, and protocol adjustments as needed.
Your provider should be monitoring both efficacy markers (is the therapy doing what we expected?) and safety markers (are your liver enzymes, kidney function, and hormonal levels stable?). If a provider prescribes without scheduling follow-up, that is a red flag.
What It Costs
Peptide therapy is almost entirely out-of-pocket. Compounded peptides are not FDA-approved drugs, and insurance companies generally do not cover them. Here are realistic 2026 ranges based on the current telehealth and compounding pharmacy market.
| Item | Typical Range | Notes |
|---|---|---|
| Initial Consultation | $99–$300 | Video visit with licensed provider; some platforms include intake and first-month prescription in one fee |
| Baseline Bloodwork | $100–$400 | Depends on panel scope; some providers accept recent labs from your PCP |
| BPC-157 (monthly) | $150–$350 | Injectable or oral; varies by pharmacy and dosage |
| TB-500 (monthly) | $150–$300 | Often prescribed alongside BPC-157 in recovery protocols |
| CJC-1295/Ipamorelin (monthly) | $200–$400 | Growth hormone secretagogue combo; common in anti-aging protocols |
| GHK-Cu (monthly) | $100–$250 | Skin rejuvenation and wound healing; topical or injectable |
| Follow-Up Visits | $50–$150 | Typically every 4–8 weeks initially |
| Follow-Up Bloodwork | $75–$200 | Usually at 8–12 weeks; may be a smaller panel than baseline |
| Cold Shipping | $10–$25 | Per shipment; some providers include in the monthly fee |
A realistic first-month budget for a single-peptide protocol: $350–$750 including consultation, bloodwork, and the medication itself. Monthly ongoing costs settle into the $150–$400 range for the medication plus periodic follow-ups and labs.
Some telehealth platforms offer subscription models that bundle the consultation, medication, and follow-ups into a flat monthly fee. Others charge separately for each component. Neither model is inherently better — compare the total cost over 3 months rather than just the listed monthly fee, and make sure follow-up labs and consultations are included, not extra.
How to Find a Provider
The peptide telehealth market has grown rapidly since the Category 2 removals in April 2026. Multiple platforms now offer physician-supervised peptide protocols with integrated pharmacy fulfillment. When evaluating a provider, here is what to look for and what to avoid.
What a Legitimate Provider Looks Like
A licensed physician (MD/DO), nurse practitioner (NP), or physician assistant (PA) conducts the consultation. They require bloodwork before prescribing, not after. They discuss the clinical rationale, the evidence base and its limitations, and set a follow-up schedule. Their partner pharmacy is a licensed 503A compounding pharmacy with verifiable credentials. They provide clear pricing with no hidden fees.
What Should Concern You
A provider who prescribes without reviewing bloodwork. A platform that lets you “choose your peptide” from a product menu without a clinical evaluation. A pharmacy that ships without a prescription. Any provider who claims peptides are “FDA approved” — they are not. Pricing that seems dramatically below market — the pharmacy costs are real, and unusually low prices often mean corners are being cut on sourcing or testing.
Companies selling peptides labeled “for research use only” are not providers. They are chemical suppliers. Using research-grade peptides for human administration is a different pathway with different legal standing and different quality assurance. The FDA has issued more than 50 warning letters to sellers and clinics on this basis between 2024 and 2026. If you want physician-supervised therapy with pharmaceutical-grade compounds, you need a prescribing provider and a compounding pharmacy — not a research vendor. See our BPC-157 legal status guide for the full distinction.
The Regulatory Context
Understanding the legal framework helps you evaluate what you’re being offered. Here is the short version; our 503A vs 503B explainer and PCAC results breakdown cover the details.
The peptides most commonly prescribed through telehealth — BPC-157, TB-500, GHK-Cu, CJC-1295, Semax, and others — are currently in Category 1 under the FDA’s interim enforcement framework. This means the FDA is not taking enforcement action against licensed 503A pharmacies that compound them with a valid prescription. Six of these received favorable PCAC advisory votes in July 2026, and the formal rulemaking to place them on the 503A Bulks List is expected to conclude sometime in 2027.
The practical effect: the prescribe-and-compound pathway is available now and providers are using it. The legal standing will be fully codified once the rulemaking process is complete. If you start a protocol now, you are operating within an active enforcement framework that the FDA has publicly articulated, but the formal authorization is still pending.
This guide describes the process for accessing peptide therapy, not a recommendation to pursue it. Whether peptide therapy is appropriate for your situation is a clinical determination that belongs between you and a licensed healthcare provider who has reviewed your medical history and bloodwork. PeptideOnline provides educational content and does not prescribe, compound, or sell peptides.
Frequently Asked Questions
Sources
Cost ranges are based on publicly listed pricing from multiple telehealth peptide platforms and compounding pharmacies active in 2026. Regulatory framework references: FDA interim enforcement categories, Section 503A of the FD&C Act, 21 C.F.R. § 216.23. Bloodwork panel information drawn from clinical protocols published by peptide therapy providers and standard laboratory reference ranges.